AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi and Rinvoq position it well for long-term growth. AbbVie came into existence after Abbott Laboratories divested its pharmaceutical division. AbbVie enjoys leadership positions in key therapeutic areas including immunology, hematologic oncology, neuroscience, aesthetics, eye care and womens' health. Humira is approved for several autoimmune diseases like rheumatoid arthritis, active psoriatic arthritis, active ankylosing spondylitis, Crohn's disease and others. Imbruvica became part of the company's portfolio following the Pharmacyclics acquisition. Other key drugs include Venclexta, Botox Cosmetic, Botox Therapeutics, Vraylar, Skyrizi and Rinvoq....
+See More2018-12-19 17:41:00 Wednesday ET
Tencent Music Entertainment debuts its IPO on NYSE to strike a chord with stock market investors. Tencent Music goes public and marks the biggest IPO by a m
2018-11-13 12:30:00 Tuesday ET
President Trump promises a great trade deal with China as Americans mull over mid-term elections. President Trump wants to reach a trade accord with Chinese
2018-08-21 11:40:00 Tuesday ET
President Trump criticizes his new Fed Chair Jerome Powell for accelerating the current interest rate hike with greenback strength. This criticism overshado
2018-10-17 12:33:00 Wednesday ET
The Trump administration blames China for egregious currency misalignment, but this criticism cannot confirm *currency manipulation* on the part of the Chin
2020-11-03 08:30:00 Tuesday ET
Agile lean enterprises break down organizational silos to promote smart collaboration for better profitability and customer loyalty. Heidi Gardner (2017
2019-08-20 07:33:00 Tuesday ET
The recent British pound depreciation is a big Brexit barometer. Britain appoints former London mayor and Foreign Secretary Boris Johnson as the prime minis